NewsBenzingaBiogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin;... Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin;... Benzinga 2026.10.02 15:26 (GMT+0) Open on Benzinga Other news Exclusive | Some Wall Street Leaders are Weighing Bailing on ‘Davos in the Desert’ After Attacks on Riyadh Why 1 Analyst Is Cooling Their Stance on Red-Hot DELL Stock Intel vs. AMD: The CPU Comeback Has Become a 2-Stock Fight, But 1 Is the Better Buy Anthropic says it’s committing 5% of its shares to a ‘public benefit fund’ Taiwan Semiconductor Could Partner With Elon Musk’s Terafab, but It Has 1 Condition Wall Street Brunch: SpaceX, Tesla, Meta On The Earnings Card (undefined:SPCX)
Exclusive | Some Wall Street Leaders are Weighing Bailing on ‘Davos in the Desert’ After Attacks on Riyadh
